Shire PLC (NASDAQ:SHPG) dropped 0.7% during mid-day trading on Friday . The company traded as low as $187.22 and last traded at $188.19, with a volume of 608,163 shares. The stock had previously closed at $189.52.

SHPG has been the topic of a number of analyst reports. Bank of America Corp. reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday, March 30th. BTIG Research reiterated a “buy” rating and set a $230.00 price objective on shares of Shire PLC in a research note on Tuesday, April 5th. Jefferies Group reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, April 12th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research note on Saturday, April 16th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $240.00 price objective on shares of Shire PLC in a research note on Saturday, April 16th. Two investment analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $236.13.

The stock has a market capitalization of $37.12 billion and a PE ratio of 28.29. The company’s 50-day moving average is $181.94 and its 200-day moving average is $176.20.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.05 by $0.14. During the same quarter in the previous year, the firm posted $2.08 earnings per share. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.71 billion. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. Analysts anticipate that Shire PLC will post $12.54 EPS for the current fiscal year.

Several hedge funds recently added to or reduced their stakes in SHPG. ProShare Advisors LLC raised its stake in Shire PLC by 0.9% in the fourth quarter. ProShare Advisors LLC now owns 37,741 shares of the biopharmaceutical company’s stock worth $7,737,000 after buying an additional 340 shares during the last quarter. Jennison Associates LLC raised its stake in Shire PLC by 12.8% in the fourth quarter. Jennison Associates LLC now owns 7,196,669 shares of the biopharmaceutical company’s stock worth $1,475,317,000 after buying an additional 819,188 shares during the last quarter. Morgan Stanley raised its stake in Shire PLC by 17.4% in the fourth quarter. Morgan Stanley now owns 1,120,057 shares of the biopharmaceutical company’s stock worth $229,611,000 after buying an additional 166,169 shares during the last quarter. CAM Group Holding A S raised its stake in Shire PLC by 111.7% in the fourth quarter. CAM Group Holding A S now owns 104,324 shares of the biopharmaceutical company’s stock worth $21,386,000 after buying an additional 55,050 shares during the last quarter. Finally, Columbus Circle Investors raised its stake in Shire PLC by 77.4% in the fourth quarter. Columbus Circle Investors now owns 78,628 shares of the biopharmaceutical company’s stock worth $16,119,000 after buying an additional 34,305 shares during the last quarter.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.